RecruitingEarly Phase 1NCT07205315

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Grit Biotechnology
Intervention
GT801 Injection(biological)
Enrollment
28 enrolled
Eligibility
18-75 years · All sexes
Timeline
20252028

Study locations (2)

Collaborators

Zhengzhou Yihe Hospital · Institute of Hematology & Blood Diseases Hospital, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07205315 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials